The EBITDA Illusion: Why DSOs Buy You at 5x and Trade at 14x (And How to Keep the Difference)

Private Equity isn’t smarter than you; they just know how to format a P&L. They have mastered a financial mechanism that allows them to acquire your life’s work for a fraction of its market value, repackage it, and sell it for a fortune. This mechanism is called Multiple Arbitrage, and it’s the engine driving the consolidation of the dental industry.

This report will dissect the math, expose the mindset that makes dentists vulnerable, and provide a data-driven defense to ensure you keep the wealth you’ve created.

Section 1: The Math of Arbitrage

The core of the DSO and private equity playbook is Multiple Arbitrage. It is the practice of buying smaller assets valued at a low multiple of their earnings, bundling them into a larger portfolio, and then having that portfolio valued at a significantly higher multiple.

The 2025-2026 M&A market provides a stark illustration of this wealth transfer. According to the TUSK Practice Sales 2026 Dental M&A Market Report, 61% of surveyed DSOs reported that their private equity backers are expecting a moderate or high uptick in acquisition activity in 2026. The appetite is growing. And the math is brutal.

The Arbitrage Gap

Smaller “add-on” practices are being acquired for 5-8x Adjusted EBITDA. However, the larger “platform” buyers acquiring them trade at multiples of 9-14x EBITDA.

Let’s translate this into hard numbers. A private practice generating $1 million in EBITDA is acquired at a 5x multiple. The acquirer bundles this practice into a larger entity valued at 12x. The original $1 million of EBITDA is now worth $12 million on paper.

Your EBITDA: $1,000,000

You Sell At

5x = $5M

→

They Trade At

12x = $12M

Where did the extra $7 million go?

This isn’t financial wizardry. It’s a calculated, repeatable process. They are buying your practice to dress up their portfolio for the next sale. The question is: will you let them do it on their terms, or yours?

Section 2: The Villain (The “Tax-Minimization” Mindset)

For decades, the primary financial goal for most dentists has been to show the IRS as little profit as possible. Every financial decision is filtered through the lens of tax reduction. This tax-minimization mindset, while saving you pennies on your annual tax bill, costs you millions at the exit.

Buyers don’t value your practice based on its tax return. In fact, they love your tax return because it gives them ammo to drive the price down. They value you based on Adjusted EBITDA—your true cash-generating potential.

The $50,000 Mistake

The Move: You expense a $10,000 personal family vacation through the practice.

The “Win”: You save $3,700 in taxes (assuming a 37% bracket).

The Loss: You lower your EBITDA by $10,000. At a 5x multiple, you just lowered your sale price by $50,000.

You spent $50,000 to save $3,700.

You cannot optimize for Taxes and Valuation at the same time. One saves you pennies; the other costs you millions.

Section 3: The Solution (Forensic Recasting)

Adjusted EBITDA is the great equalizer. It is your reported net income with specific, justifiable expenses added back in. This process, known as recasting, transforms your tax-focused P&L into a valuation-focused one.

Consider a practice with $2 million in revenue that shows only $100,000 in net income. At a 5x multiple, this practice appears to be worth $500,000. Now, let’s apply a forensic recasting:

Line Item

Amount

Reported Net Income

$100,000

+ Owner Salary Above Market Rate

+$150,000

+ Non-Working Family Salaries

+$50,000

+ Personal Auto & Travel

+$25,000

+ One-Time Legal Fees

+$15,000

+ Depreciation & Amortization

+$20,000

+ Supply Cost Inefficiency (Benchmarked)

+$60,000

Adjusted EBITDA

$420,000

With a recast EBITDA of $420,000 at 5x multiple:

Before Recasting

$500,000

→

After Recasting

$2,100,000

Unlocked Exit Value: +$1,600,000

Section 4: The Defense (Data vs. Opinion)

Buyers will not simply accept your add-backs on faith. They will fight them. The TUSK report explicitly states that “differing tolerance for add-backs” is a primary reason for failed deals. This is where data becomes your shield.

Hard Add-Backs are objective. A buyer may question them, but they cannot deny them if you have the invoices (e.g., non-working family salaries or one-time legal fees).

Soft Add-Backs are where the war is won or lost.

Take the $60,000 in supply cost inefficiency from our example. A sophisticated buyer will claim that they are the ones bringing the purchasing power to fix that, so they deserve to keep the upside.

You must use data to prove that this is a “process anomaly” you have already identified and corrected, forcing them to pay for the adjusted reality. You can’t just claim your costs are high; you must prove it by benchmarking against industry data.

You cannot walk into a negotiation with opinions. You must present a data-driven case, benchmarked against the industry, that proves the true cash-generating power of your practice.

The Call to Action

The game of dental M&A is being played whether you choose to participate or not. The arbitrage gap exists because sellers are uninformed and unprepared. The buyers have the data. They have the playbook.

The only way to level the playing field is to arm yourself with the same tools.

Stop guessing. Start strategizing.

Get a data-driven valuation analysis that arms you with the same intelligence the buyers use.

Run Your Practice Valuation →

References

[1] TUSK Practice Sales. (2026, January 16). TUSK Practice Sales Releases 2026 Dental M&A Market Report.

[2] Focus Investment Banking. (2025, December 5). Dental Practice EBITDA.

[3] DentalPost. (2025). 2025 Dental Salary Survey.

[4] Percentology. (2025, May 27). Latest Dental Practice Overhead Percentages.